Current and future treatments of bone metastases

Expert Opinion on Emerging Drugs

Volumn 13, Issue 4, 2008, Pages 609-627

  Clark, J C M ^a   Dass, C R ^a   Choong, Peter F M ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

Bone; Cancer; Metastasis; Osteoblast; Osteoclast; Therapy

Indexed keywords

ALENDRONIC ACID; ATRASENTAN; BALICATIB; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; DASATINIB; DENOSUMAB; ESTRAMUSTINE; LEXIDRONAM SAMARIUM SM 153; MINODRONIC ACID; N (5 CHLORO 1,3 BENZODIOXOL 4 YL) 7 [2 (4 METHYL 1 PIPERAZINYL)ETHOXY] 5 (TETRAHYDRO 2H PYRAN 4 YLOXY) 4 QUINAZOLINAMINE; ODANACATIB; PAMIDRONIC ACID; RELACATIB; ZOLEDRONIC ACID;

BONE DISEASE; BONE METASTASIS; BONE PAIN; CANCER PAIN; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; DRUG MECHANISM; FRACTURE; FROZEN BONE; GASTRITIS; HUMAN; IMMUNE DEFICIENCY; JAW OSTEONECROSIS; NEPHROTOXICITY; OSTEOCLAST; OSTEOLYSIS; PATHOLOGIC FRACTURE; REVIEW; UVEITIS;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DRUGS, INVESTIGATIONAL; HUMANS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 58149269416     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728210802584217     Document Type: Review

References (188)

1. Clezardin P, Teti A. Bone metastasis: pathogenesis and therapeutic implications. Clin Exp Metastasis 2007;24(8):599-608
2. Coleman RE. Skeletal complications of malignancy. Cancer 1997;80(8 Suppl):1588-94
3. Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. Br J Cancer 1987;55(1):61-6
4. Domchek SM, Younger J, Finkelstein DM, Seiden MV. Predictors of skeletal complications in patients with metastatic breast carcinoma. Cancer 2000;89(2):363-8
5. Roudier MP, True LD, Higano CS, et al. Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone. Hum Pathol 2003;34(7):646-53
6. Israeli RS. Managing bone loss and bone metastases in prostate cancer patients: a focus on bisphosphonate therapy. Rev Urol 2008;10(2):99-110
7. Perez EA, Weilbaecher K. Aromatase inhibitors and bone loss. Oncology (Williston Park) 2006;20(9):1029-39; discussion 39-40,42,48
8. Johnston AD. Pathology of metastatic tumors in bone. Clin Orthop Relat Res 1970;73:8-32
9. Cotran RS, Kumar V, Collins T, Robbins SL. Robbins pathologic basis of disease. Philadelphia: Saunders; 1999
10. Russo P. Renal cell carcinoma: presentation, staging, and surgical treatment. Semin Oncol 2000;27(2):160-76
11. Lin PP, Mirza AN, Lewis VO, et al. Patient survival after surgery for osseous metastases from renal cell carcinoma. J Bone Joint Surg Am 2007;89(8):1794-801
12. Chatziioannou AN, Johnson ME, Pneumaticos SG, et al. Preoperative embolization of bone metastases from renal cell carcinoma. Eur Radiol 2000;10(4):593-6
13. Dürr HR, Maier M, Pfahler M, et al. Surgical treatment of osseous metastases in patients with renal cell carcinoma. Clin Orthop Relat Res 1999;367:283-90
14. Weber KL, Doucet M, Price JE. Renal cell carcinoma bone metastasis: epidermal growth factor receptor targeting. Clin Orthop Relat Res 2003;415(Suppl):S86-94
15. Chirgwin JM, Guise TA. Skeletal metastases: decreasing tumor burden by targeting the bone microenvironment. J Cell Biochem 2007;102(6):1333-42
16. Oyajobi BO. Multiple myeloma/hypercalcemia. Arthritis Res Ther 2007;9(Suppl 1):S4
17. Redzepovic J, Weinmann G, Ott I, Gust R. Current trends in multiple myeloma management. J Int Med Res 2008;36(3):371-86
18. Dürr HR, Müller PE, Lenz T, et al. Surgical treatment of bone metastases in patients with breast cancer. Clin Orthop Relat Res 2002;396:191-6
19. Stresing V, Daubiné F, Benzaid I, et al. Bisphosphonates in cancer therapy. Cancer Lett 2007;257(1):16-35
20. Dunstan CR, Felsenberg D, Seibel MJ. Therapy insight: the risks and benefits of bisphosphonates for the treatment of tumor-induced bone disease. Nat Clin Pract Oncol 2007;4(1):42-55
21. Weber KL, O'Connor MI. Operative treatment of long bone metastases: focus on the femur. Clin Orthop Relat Res 2003;415 (Suppl):S276-8
22. Thai DM, Kitagawa Y, Choong PF. Outcome of surgical management of bony metastases to the humerus and shoulder girdle: a retrospective analysis of 93 patients. Int Semin Surg Oncol 2006;3:5
23. Clohisy DR, Le CT, Cheng EY, et al. Evaluation of the feasibility of and results of measuring health-status changes in patients undergoing surgical treatment for skeletal metastases. J Orthop Res 2000;18(1):1-9
24. Boyle MJ, Hornicek FJ, Robinson DS, Mnaymneh W. Internal hemipelvectomy for solitary pelvic thyroid cancer metastases. J Surg Oncol 2000;75(1):3-10
25. Barwood SA, Wilson JL, Molnar RR, Choong PF. The incidence of acute cardiorespiratory and vascular dysfunction following intramedullary nail fixation of femoral metastasis. Acta Orthop Scand 2000;71(2):147-52
26. Healey JH, Shannon F, Boland P, Diresta GR. PMMA to stabilize bone and deliver antineoplastic and antiresorptive agents. Clin Orthop Relat Res 2003;(415 Suppl):S263-75
27. Dall GF, Simpson PM, Breusch SJ. In vitro comparison of Refobacin-Palacos R with Refobacin Bone Cement and Palacos R + G. Acta Orthop 2007;78(3):404-11
28. Fröschle GW, Mählitz J, Langendorff HU, et al. Release of daunorubicin from polymethylmethacrylate for the improvement of the local growth control of bone metastasis animal experiments. Anticancer Res 1997;17(2A):995-1002
29. Hernigou P, Thiéry JP, Benoit J, et al. Methotrexate diffusion from acrylic cement. Local chemotherapy for bone tumours. J Bone Joint Surg Br 1989;71(5):804-11
30. Wang HM, Galasko CS, Crank S, et al. Methotrexate loaded acrylic cement in the management of skeletal metastases. Biomechanical, biological, and systemic effect. Clin Orthop Relat Res 1995;312:173-86
31. Birkenhauer P, Yang Z, Gander B. Preventing restenosis in early drug-eluting stent era: recent developments and future perspectives. J Pharm Pharmacol 2004;56(11):1339-56
32. Samartzis D, Khanna N, Shen FH, An HS. Update on bone morphogenetic proteins and their application in spine surgery. J Am Coll Surg 2005;200(2):236-48
33. Luginbuehl V, Meinel L, Merkle HP, Gander B. Localized delivery of growth factors for bone repair. Eur J Pharm Biopharm 2004;58(2):197-208
34. Leach JK, Mooney DJ. Bone engineering by controlled delivery of osteoinductive molecules and cells. Expert Opin Biol Ther 2004;4(7):1015-27
35. Kandziora F, Schmidmaier G, Schollmeier G, et al. IGF-I and TGF-beta1 application by a poly-(D,L-lactide)-coated cage promotes intervertebral bone matrix formation in the sheep cervical spine. Spine 2002;27(16):1710-23
36. Lin A, Ray ME. Targeted and systemic radiotherapy in the treatment of bone metastasis. Cancer Metastasis Rev 2006;25(4):669-75
37. O'Sullivan B, Davis AM, Turcotte R, et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. Lancet 2002;359(9325):2235-41
38. Townsend PW, Rosenthal HG, Smalley SR, et al. Impact of postoperative radiation therapy and other perioperative factors on outcome after orthopedic stabilization of impending or pathologic fractures due to metastatic disease. J Clin Oncol 1994;12(11):2345-50
39. Tong D, Gillick L, Hendrickson FR. The palliation of symptomatic osseous metastases: final results of the Study by the Radiation Therapy Oncology Group. Cancer 1982;50(5):893-9
40. Vargha ZO, Glicksman AS, Boland J. Single-dose radiation therapy in the palliation of metastatic disease. Radiology 1969;93(5):1181-4
41. Poulter CA, Cosmatos D, Rubin P, et al. A report of RTOG 8206: a Phase III study of whether the addition of single dose hemibody irradiation to standard fractionated local field irradiation is more effective than local field irradiation alone in the treatment of symptomatic osseous metastases. Int J Radiat Oncol Biol Phys 1992;23(1):207-14
42. Lewington VJ, Mcewan AJ, Ackery DM, et al. A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone. Eur J Cancer 1991;27(8):954-8
43. Buchali K, Correns HJ, Schuerer M, et al. Results of a double blind study of 89-strontium therapy of skeletal metastases of prostatic carcinoma. Eur J Nucl Med 1988;14(7-8):349-51
44. Anderson PM, Wiseman GA, Dispenzieri A, et al. High-dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases. J Clin Oncol 2002;20(1):189-96
45. Sartor O, Reid RH, Hoskin PJ, et al. Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology 2004;63(5):940-5
46. Serafini AN. Samarium Sm-153 lexidronam for the palliation of bone pain associated with metastases. Cancer 2000;88(12 Suppl):2934-9
47. Dickie GJ, Macfarlane D. Strontium and samarium therapy for bone metastases from prostate carcinoma. Australas Radiol 1999;43(4):476-9
48. Ricci S, Boni G, Pastina I, et al. Clinical benefit of bone-targeted radiometabolic therapy with 153Sm-EDTMP combined with chemotherapy in patients with metastatic hormone-refractory prostate cancer. Eur J Nucl Med Mol Imaging 2007;34(7):1023-30
49. Ory B, Blanchard F, Battaglia S, et al. Zoledronic acid activates the DNA S-phase checkpoint and induces osteosarcoma cell death characterized by apoptosis-inducing factor and endonuclease-G translocation independently of p53 and retinoblastoma status. Mol Pharmacol 2007;71(1):333-43
50. Wood J, Bonjean K, Ruetz S, et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 2002;302(3):1055-61
51. Giraudo E, Inoue M, Hanahan D. An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest 2004;114(5):623-33
52. Soltau J, Zirrgiebel U, Esser N, et al. Antitumoral and antiangiogenic efficacy of bisphosphonates in vitro and in a murine RENCA model. Anticancer Res 2008;28(2A):933-41
53. Aparicio A, Gardner A, Tu Y, et al. In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates. Leukemia 1998;12(2):220-9
54. Stearns ME. Alendronate blocks TGF-beta1 stimulated collagen 1 degradation by human prostate PC-3 ML cells. Clin Exp Metastasis 1998;16(4):332-39
55. Coleman RE. Optimising treatment of bone metastases by Aredia(TM) and Zometa(TM). Breast Cancer 2000;7(4):361-9
56. Zhang S, Gangal G, Uludaäÿ H. 'Magic bullets' for bone diseases: progress in rational design of bone-seeking medicinal agents. Chem Soc Rev 2007;36(3):507-31
57. Kumar D, Kumar V, Little DG, et al. Evaluation of biodistribution by local versus systemic administration of 99mTc-labeled pamidronate. J Orthop Sci 2006;11(5):512-20
58. Hall DG, Stoica G. Effect of the bisphosphonate risedronate on bone metastases in a rat mammary adenocarcinoma model system. J Bone Miner Res 1994;9(2):221-30
59. Yoneda T, Sasaki A, Dunstan C, et al. Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2. J Clin Invest 1997;99(10):2509-17
60. Clohisy DR, O'Keefe PF, Ramnaraine ML. Pamidronate decreases tumor-induced osteoclastogenesis in osteopetrotic mice. J Orthop Res 2001;19(4):554-8
61. Magnetto S, Boissier S, Delmas PD, Clezardin P. Additive antitumor activities of taxoids in combination with the bisphosphonate ibandronate against invasion and adhesion of human breast carcinoma cells to bone. Int J Cancer 1999;83(2):263-9
62. Rosen LS, Gordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 2003;98(8):1735-44
63. Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a Phase III, double-blind, comparative trial. Cancer J 2001;7(5):377-87
64. Rosen LS, Gordon D, Tchekmedyian S, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a Phase III, double-blind, randomized trial - the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 2003;21(16):3150-7
65. Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002;94(19):1458-68
66. Pavlakis N, Schmidt R, Stockler M. Bisphosphonates for breast cancer. Cochrane Database Syst Rev 2005;(3):CD003474
67. Kretzschmar A, Wiege T, Al-Batran SE, et al. Rapid and sustained influence of intravenous zoledronic Acid on course of pain and analgesics consumption in patients with cancer with bone metastases: a multicenter open-label study over 1 year. Support Cancer Ther 2007;4(4):203-10
68. McKeage K, Plosker GL. Zoledronic acid: a pharmacoeconomic review of its use in the management of bone metastases. Pharmacoeconomics 2008;26(3):251-68
69. Mortensen M, Lawson W, Montazem A. Osteonecrosis of the jaw associated with bisphosphonate use: Presentation of seven cases and literature review. Laryngoscope 2007;117(1):30-4
70. Mashiba T, Turner CH, Hirano T, et al. Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 2001;28(5):524-31
71. Odvina CV, Zerwekh JE, Rao DS, et al. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005;90(3):1294-301
72. Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006;296(24):2927-38
73. Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007;22(10):1479-91
74. Murad OM, Arora S, Farag AF, Guber HA. Bisphosphonates and osteonecrosis of the jaw: a retrospective study. Endocr Pract 2007;13(3):232-8
75. Novince CM, Ward BB, McCauley LK. Osteonecrosis of the Jaw: An Update and Review of Recommendations. Cells Tissues Organs 2008 Sep 1 [Epub ahead of print]
76. Dimopoulos MA, Kastritis E, Bamia C, et al. Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol 9 August 2008 [Epub ahead of print]
77. Sekine I, Sumi M, Saijo N. Local control of regional and metastatic lesions and indication for systemic chemotherapy in patients with non-small cell lung cancer. Oncologist 2008;13(Suppl 1):21-7
78. Harvey HA. Issues concerning the role of chemotherapy and hormonal therapy of bone metastases from breast carcinoma. Cancer 1997;80(8 Suppl)1646-51
79. Scheid V, Buzdar AU, Smith TL, Hortobagyi GN. Clinical course of breast cancer patients with osseous metastasis treated with combination chemotherapy. Cancer 1986;58(12):2589-93
80. Bergh J, Jönsson PE, Glimelius B, Nygren P. A systematic overview of chemotherapy effects in breast cancer. Acta Oncol 2001;40(2-3):253-81
81. Clark PE, Torti FM. Prostate cancer and bone metastases: medical treatment. Clin Orthop Relat Res 2003;(415 Suppl):S148-57
82. Müller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001;410(6824):50-6
83. Libura J, Drukala J, Majka M, et al. CXCR4-SDF-1 signaling is active in rhabdomyosarcoma cells and regulates locomotion, chemotaxis, and adhesion. Blood 2002;100(7):2597-606
84. Murakami T, Maki W, Cardones AR, et al. Expression of CXC chemokine receptor-4 enhances the pulmonary metastatic potential of murine B16 melanoma cells. Cancer Res 2002;62(24):7328-34
85. Smith MC, Luker KE, Garbow Jr, et al. CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Res 2004;64(23):8604-12
86. Taichman RS, Cooper C, Keller ET, et al. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res 2002;62(6):1832-7
87. Strahm B, Durbin AD, Sexsmith E, Malkin D. The CXCR4-SDF1alpha axis is a critical mediator of rhabdomyosarcoma metastatic signaling induced by bone marrow stroma. Clin Exp Metastasis 2008;25(1):1-10
88. Chinni SR, Yamamoto H, Dong Z, et al. CXCL12/CXCR4 transactivates HER2 in lipid rafts of prostate cancer cells and promotes growth of metastatic deposits in bone. Mol Cancer Res 2008;6(3):446-57
89. Tang CH, Tan TW, Fu WM, Yang RS. Involvement of matrix metalloproteinase-9 in stromal cell-derived factor-1/CXCR4 pathway of lung cancer metastasis. Carcinogenesis 2008;29(1):35-43
90. Chinni SR, Sivalogan S, Dong Z, et al. CXCL12/CXCR4 signaling activates Akt-1 and MMP-9 expression in prostate cancer cells: the role of bone microenvironment-associated CXCL12. Prostate 2006;66(1):32-48
91. Miwa S, Mizokami A, Keller ET, et al. The bisphosphonate YM529 inhibits osteolytic and osteoblastic changes and CXCR-4-induced invasion in prostate cancer. Cancer Res 2005;65(19):8818-25
92. Sun YX, Schneider A, Jung Y, et al. Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo J Bone Miner Res 2005;20(2):318-29
93. Fidler IJ, Kim SJ, Langley RR. The role of the organ microenvironment in the biology and therapy of cancer metastasis. J Cell Biochem 2007;101(4):927-36
94. Guise TA, Chirgwin JM. Transforming growth factor-beta in osteolytic breast cancer bone metastases. Clin Orthop Relat Res 2003;415(Suppl):S32-8
95. Kingsley LA, Fournier PG, Chirgwin JM, Guise TA. Molecular biology of bone metastasis. Mol Cancer Ther 2007;6(10):2609-17
96. Zhang J, Dai J, Qi Y, et al. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest 2001;107(10):1235-44
97. Chikatsu N, Takeuchi Y, Tamura Y, et al. Interactions between cancer and bone marrow cells induce osteoclast differentiation factor expression and osteoclast-like cell formation in vitro. Biochem Biophys Res Commun 2000;267(2):632-7
98. Hofbauer LC, Heufelder AE. Osteoprotegerin and its cognate ligand: a new paradigm of osteoclastogenesis. Eur J Endocrinol 1998;139(2):152-4
99. Takayanagi H. The role of NFAT in osteoclast formation. Ann N Y Acad Sci 2007;1116:227-37
100. Vessella RL, Corey E. Targeting factors involved in bone remodeling as treatment strategies in prostate cancer bone metastasis. Clin Cancer Res 2006;12(20 Pt 2):s6285-90
101. Morrissey C, Vessella RL. The role of tumor microenvironment in prostate cancer bone metastasis. J Cell Biochem 2007;101(4):873-86
102. Mitsiades CS, Mcmillin DW, Klippel S, et al. The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies. Hematol Oncol Clin North Am 2007;21(6):1007-34, vii-viii
103. Chirgwin JM, Guise TA. Interactions between tumor and bone alter the phenotypes of both. J Musculoskelet Neuronal Interact 2003;3(4):278-81; discussion 92-4
104. Guise TA, Yin JJ, Mohammad KS. Role of endothelin-1 in osteoblastic bone metastases. Cancer 2003;97(3 Suppl):779-84
105. Nelson JB, Hedican SP, George DJ, et al. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med 1995;1(9):944-9
106. Casey ML, Byrd W, Macdonald PC. Massive amounts of immunoreactive endothelin in human seminal fluid. J Clin Endocrinol Metab 1992;74(1):223-5
107. Prayer-Galetti T, Rossi GP, Belloni AS, et al. Gene expression and autoradiographic localization of endothelin-1 and its receptors A and B in the different zones of the normal human prostate. J Urol 1997;157(6):2334-9
108. Arai H, Hori S, Aramori I, et al. Cloning and expression of a cDNA encoding an endothelin receptor. Nature 1990;348(6303):730-2
109. Sakurai T, Yanagisawa M, Takuwa Y, et al. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature 1990;348(6303):732-5
110. Hall CL, Bafico A, Dai J, et al. Prostate cancer cells promote osteoblastic bone metastases through Wnts. Cancer Res 2005;65(17):7554-60
111. Mitsiades CS, Mitsiades NS, Richardson PG, et al. Multiple myeloma: a prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment. J Cell Biochem 2007;101(4):950-68
112. Stoch SA, Wagner JA. Cathepsin K inhibitors: a novel target for osteoporosis therapy. Clin Pharmacol Ther 2008;83(1):172-6
113. Le Gall C, Bellahcène A, Bonnelye E, et al. A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden. Cancer Res 2007;67(20):9894-902
114. Kido A, Tsutsumi M, Iki K, et al. Overexpression of matrix metalloproteinase (MMP)-9 correlates with metastatic potency of spontaneous and 4-hydroxyaminoquinoline 1-oxide (4-HAQO)-induced transplantable osteosarcomas in rats. Cancer Lett 1999;137(2):209-16
115. Clark JC, Thomas DM, Choong PF, Dass CR. RECK - a newly discovered inhibitor of metastasis with prognostic significance in multiple forms of cancer. Cancer Metastasis Rev 2007;26(3-4):675-83
116. Pei Y, Harvey A, Yu XP, et al. Differential regulation of cytokine-induced MMP-1 and MMP-13 expression by p38 kinase inhibitors in human chondrosarcoma cells: potential role of Runx2 in mediating p38 effects. Osteoarthritis Cartilage 2006;14(8):749-58
117. Pratap J, Javed A, Languino LR, et al. The Runx2 osteogenic transcription factor regulates matrix metalloproteinase 9 in bone metastatic cancer cells and controls cell invasion. Mol Cell Biol 2005;25(19):8581-91
118. Pillay V, Dass CR, Choong PF. The urokinase plasminogen activator receptor as a gene therapy target for cancer. Trends Biotechnol 2007;25(1):33-9
119. Choong PF, Nadesapillai AP. Urokinase plasminogen activator system: a multifunctional role in tumor progression and metastasis. Clin Orthop Relat Res 2003;(415 Suppl):S46-58
120. Margheri F, D'alessio S, Serratí S, et al. Effects of blocking urokinase receptor signaling by antisense oligonucleotides in a mouse model of experimental prostate cancer bone metastases. Gene Ther 2005;12(8):702-14
121. D'alessio S, Margheri F, Pucci M, et al. Antisense oligodeoxynucleotides for urokinase-plasminogen activator receptor have anti-invasive and anti-proliferative effects in vitro and inhibit spontaneous metastases of human melanoma in mice. Int J Cancer 2004;110(1):125-33
122. Wong BR, Besser D, Kim N, et al. TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src. Mol Cell 1999;4(6):1041-9
123. Rucci N, Susa M, Teti A. Inhibition of protein kinase c-Src as a therapeutic approach for cancer and bone metastases. Anticancer Agents Med Chem 2008;8(3):342-9
124. Tanaka S, Amling M, Neff L, et al. c-Cbl is downstream of c-Src in a signalling pathway necessary for bone resorption. Nature 1996;383(6600):528-31
125. Schlessinger J. New roles for Src kinases in control of cell survival and angiogenesis. Cell 2000;100(3):293-6
126. Glantschnig H, Fisher JE, Wesolowski G, et al. M-CSF, TNFalpha and RANK ligand promote osteoclast survival by signaling through mTOR/S6 kinase. Cell Death Differ 2003;10(10):1165-77
127. Soriano P, Montgomery C, Geske R, Bradley A. Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell 1991;64(4):693-702
128. Honore P, Rogers SD, Schwei MJ, et al. Murine models of inflammatory, neuropathic and cancer pain each generates a unique set of neurochemical changes in the spinal cord and sensory neurons. Neuroscience 2000;98(3):585-98
129. Luger NM, Honore P, Sabino MA, et al. Osteoprotegerin diminishes advanced bone cancer pain. Cancer Res 2001;61(10):4038-47
130. Honore P, Luger NM, Sabino MA, et al. Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. Nat Med 2000;6(5):521-8
131. Ferreira SH, Romitelli M, De Nucci G. Endothelin-1 participation in overt and inflammatory pain. J Cardiovasc Pharmacol 1989;13(Suppl 5):S220-2
132. Raffa RB, Schupsky JJ, Martinez RP, Jacoby HI. Endothelin-1-induced nociception. Life Sci 1991;49(11):PL61-5
133. Piovezan AP, D'orlã©Ans-Juste P, Souza GE, Rae GA. Endothelin-1-induced ET(A) receptor-mediated nociception, hyperalgesia and oedema in the mouse hind-paw: modulation by simultaneous ET(B) receptor activation. Br J Pharmacol 2000;129(5):961-8
134. Peters CM, Lindsay TH, Pomonis JD, et al. Endothelin and the tumorigenic component of bone cancer pain. Neuroscience 2004;126(4):1043-52
135. Zhang J, Dai J, Yao Z, et al. Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone. Cancer Res 2003;63(22):7883-90
136. Oyajobi BO, Anderson DM, Traianedes K, et al. Therapeutic efficacy of a soluble receptor activator of nuclear factor kappaB-IgG Fc fusion protein in suppressing bone resorption and hypercalcemia in a model of humoral hypercalcemia of malignancy. Cancer Res 2001;61(6):2572-8
137. Holen I, Croucher PI, Hamdy FC, Eaton CL. Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. Cancer Res 2002;62(6):1619-23
138. Morony S, Capparelli C, Sarosi I, et al. Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Res 2001;61(11):4432-6
139. Croucher PI, Shipman CM, Lippitt J, et al. Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood 2001;98(13):3534-40
140. Canon JR, Roudier M, Bryant R, et al. Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis. Clin Exp Metastasis 2008;25(2):119-29
141. Green LL. Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies. J Immunol Methods 1999;231(1-2):11-23
142. Schwarz EM, Ritchlin CT. Clinical development of anti-RANKL therapy. Arthritis Res Ther 2007;9(Suppl 1):S7
143. Lipton A, Steger GG, Figueroa J, et al. Randomized active-controlled Phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol 2007;25(28):4431-7
144. Yonemori K, Fujiwara Y, Minami H, et al. Phase 1 trial of denosumab safety, pharmacokinetics, and pharmacodynamics in Japanese women with breast cancer-related bone metastases. Cancer Sci 2008;99(6):1237-42
145. Body JJ, Facon T, Coleman RE, et al. A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 2006;12(4):1221-8
146. Bachmann MF, Wong BR, Josien R, et al. TRANCE, a tumor necrosis factor family member critical for CD40 ligand-independent T helper cell activation. J Exp Med 1999;189(7):1025-31
147. Takatsuna H, Asagiri M, Kubota T, et al. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1. J Bone Miner Res 2005;20(4):653-62
148. Han KY, Yang D, Chang EJ, et al. Inhibition of osteoclast differentiation and bone resorption by sauchinone. Biochem Pharmacol 2007;74(6):911-23
149. Park CK, Kim HJ, Kwak HB, et al. Inhibitory effects of Stewartia koreana on osteoclast differentiation and bone resorption. Int Immunopharmacol 2007;7(12):1507-16
150. Wang C, Steer JH, Joyce DA, et al. 12-O-tetradecanoylphorbol-13-acetate (TPA) inhibits osteoclastogenesis by suppressing RANKL-induced NF-kappaB activation. J Bone Miner Res 2003;18(12):2159-68
151. Rahman MM, Bhattacharya A, Fernandes G. Conjugated linoleic acid inhibits osteoclast differentiation of RAW264.7 cells by modulating RANKL signaling. J Lipid Res 2006;47(8):1739-48
152. Ichikawa H, Aggarwal BB. Guggulsterone inhibits osteoclastogenesis induced by receptor activator of nuclear factor-kappaB ligand and by tumor cells by suppressing nuclear factor-kappaB activation. Clin Cancer Res 2006;12(2):662-8
153. Vasiljeva O, Reinheckel T, Peters C, et al. Emerging roles of cysteine cathepsins in disease and their potential as drug targets. Curr Pharm Des 2007;13(4):387-403
154. Peroni A, Zini A, Braga V, et al. Drug-induced morphea: report of a case induced by balicatib and review of the literature. J Am Acad Dermatol 2008;59(1):125-9
155. Desmarais S, Black WC, Oballa R, et al. Effect of cathepsin k inhibitor basicity on in vivo off-target activities. Mol Pharmacol 2008;73(1):147-56
156. Gauthier JY, Chauret N, Cromlish W, et al. The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K. Bioorg Med Chem Lett 2008;18(3):923-8
157. Irby RB, Yeatman TJ. Role of Src expression and activation in human cancer. Oncogene 2000;19(49):5636-42
158. Missbach M, Jeschke M, Feyen J, et al. A novel inhibitor of the tyrosine kinase Src suppresses phosphorylation of its major cellular substrates and reduces bone resorption in vitro and in rodent models in vivo Bone 1999;24(5):437-49
159. Recchia I, Rucci N, Funari A, et al. Reduction of c-Src activity by substituted 5,7-diphenyl-pyrrolo[2,3-d]-pyrimidines induces osteoclast apoptosis in vivo and in vitro Involvement of ERK1/2 pathway. Bone 2004;34(1):65-79
160. Rucci N, Recchia I, Angelucci A, et al. Inhibition of protein kinase c-Src reduces the incidence of breast cancer metastases and increases survival in mice: implications for therapy. J Pharmacol Exp Ther 2006;318(1):161-72
161. Fizazi K. The role of Src in prostate cancer. Ann Oncol 2007;18(11):1765-73
162. Chang YM, Bai L, Liu S, et al. Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530. Oncogene 2008;27(49):6365-75
163. Burger M, Glodek A, Hartmann T, et al. Functional expression of CXCR4 (CD184) on small-cell lung cancer cells mediates migration, integrin activation, and adhesion to stromal cells. Oncogene 2003;22(50):8093-101
164. Zannettino AC, Farrugia AN, Kortesidis A, et al. Elevated serum levels of stromal-derived factor-1alpha are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients. Cancer Res 2005;65(5):1700-9
165. Kim SY, Lee CH, Midura BV, et al. Inhibition of the CXCR4/CXCL12 chemokine pathway reduces the development of murine pulmonary metastases. Clin Exp Metastasis 2008;25(3):201-11
166. Weber KL, Doucet M, Price JE, et al. Blockade of epidermal growth factor receptor signaling leads to inhibition of renal cell carcinoma growth in the bone of nude mice. Cancer Res 2003;63(11):2940-7
167. Kim SJ, Uehara H, Yazici S, et al. Simultaneous blockade of platelet-derived growth factor-receptor and epidermal growth factor-receptor signaling and systemic administration of paclitaxel as therapy for human prostate cancer metastasis in bone of nude mice. Cancer Res 2004;64(12):4201-8
168. Mathew P, Thall PF, Jones D, et al. Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular Phase I trial in androgen-independent prostate cancer. J Clin Oncol 2004;22(16):3323-9
169. Carducci MA, Padley RJ, Breul J, et al. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, Phase II, placebo-controlled trial. J Clin Oncol 2003;21(4):679-89
170. Carducci MA, Saad F, Abrahamsson PA, et al. A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer 2007;110(9):1959-66
171. Kang Y, Siegel PM, Shu W, et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003;3(6):537-49
172. Takayanagi H, Kim S, Koga T, et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 2002;3(6):889-901
173. De La Pompa JL, Timmerman LA, Takimoto H, et al. Role of the NF-ATc transcription factor in morphogenesis of cardiac valves and septum. Nature 1998;392(6672):182-6
174. Ranger AM, Grusby MJ, Hodge MR, et al. The transcription factor NF-ATc is essential for cardiac valve formation. Nature 1998;392(6672):186-90
175. Antonescu CR. Targeted therapy of cancer: new roles for pathologists in identifying GISTs and other sarcomas. Mod Pathol 2008;21(Suppl 2):S31-6
176. Dass CR, Choong PF, Khachigian LM. DNAzyme technology and cancer therapy: cleave and let die. Mol Cancer Ther 2008;7(2):243-51
177. Dass CR, Choong PF. C-jun: pharmaceutical target for DNAzyme therapy of multiple pathologies. Pharmazie 2008;63(6):411-4
178. Dass CR, Khachigian LM, Choong PF. c-Jun knockdown sensitizes osteosarcoma to doxorubicin. Mol Cancer Ther 2008;7(7):1909-12
179. Quan GM, Choong PF. Anti-angiogenic therapy for osteosarcoma. Cancer Metastasis Rev 2006;25(4):707-13
180. Ek ET, Dass CR, Contreras KG, Choong PF. PEDF-derived synthetic peptides exhibit antitumor activity in an orthotopic model of human osteosarcoma. J Orthop Res 2007;25(12):1671-80
181. Dass CR, Choong PF. The use of chitosan formulations in cancer therapy. J Microencapsul 2008;25(4):275-9
182. Dass CR, Friedhuber AM, Khachigian LM, et al. Biocompatible chitosan-DNAzyme nanoparticle exhibits enhanced biological activity. J Microencapsul 4 April 2008 [Epub ahead of print]
183. Dass CR, Choong PF. Chitosan-mediated orally delivered nucleic acids: a gutful of gene therapy. J Drug Target 2008;16(4):257-61
184. Huang TJ, Hsu RW, Li YY, Cheng CC. Minimal access spinal surgery (MASS) in treating thoracic spine metastasis. Spine 2006;31(16):1860-3
185. Robinson D, Yassin M, Nevo Z. Cryotherapy of musculoskeletal tumors - from basic science to clinical results. Technol Cancer Res Treat 2004;3(4):371-5
186. Callstrom MR, Charboneau JW. Image-guided palliation of painful metastases using percutaneous ablation. Tech Vasc Interv Radiol 2007;10(2):120-31
187. Link TM, De Mayo R, O'donnell RJ. Radiofrequency ablation-an alternative for definitive treatment of solitary bone metastases. Eur Radiol 2007;17(11):3012-3
188. Masala S, Manenti G, Roselli M, et al. Percutaneous combined therapy for painful sternal metastases: a radiofrequency thermal ablation (RFTA) and cementoplasty protocol. Anticancer Res 2007;27(6C):4259-62